» Articles » PMID: 12828856

Selection of Oligonucleotide Aptamers with Enhanced Uptake and Activation of Human Leukemia B Cells

Overview
Journal Hum Gene Ther
Specialties Genetics
Pharmacology
Date 2003 Jun 28
PMID 12828856
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical use of oligonucleotide (ODN) therapeutics has been hampered by their limited ability to penetrate intact cells. To identify ODN properties that would facilitate cellular uptake, we developed a repetitive selection procedure using an ODN library containing at least 10(14) different molecules and human B lymphoma cells as a target. Natural phosphodiester single-stranded DNA ODNs (R-aptamers) were obtained after 10 rounds of selection. A common feature in the R-aptamers was guanine-rich 3' terminal sequences, and many also contained potential immunostimulatory (ISS) CpG sequence motifs. Two R-aptamers (R10-60 and D-R15-8) with the predominant shared characteristics were selected for further study on primary human chronic lymphocytic leukemia (CLL) B cells, which are well known to be difficult to transfect and activate. Flow cytometry analysis of the CLL cells demonstrated that the fluorochrome-labeled R-aptamers were internalized much more efficiently than nonselected random sequence ODN. Studies on sequence modifications indicated that efficient uptake required ODN multimerization, that was promoted by guanine-rich sequences at the 3' terminus. In addition, CLL cells that were exposed to the aggregating R-aptamers containing CpG motifs were strongly activated, as indicated by upregulation of CD40 levels as compared to cells treated with nonaggregating CpG R-aptamers. Together, these findings suggest that the sequence compositions in R-aptamers that promote multimerization and contain optimal ISS CpG motifs facilitate the delivery of ISS-ODN to CLL cells and enhance the activation of these cells.

Citing Articles

New Insights into Aptamers: An Alternative to Antibodies in the Detection of Molecular Biomarkers.

Domsicova M, Korcekova J, Poturnayova A, Breier A Int J Mol Sci. 2024; 25(13).

PMID: 38999943 PMC: 11240909. DOI: 10.3390/ijms25136833.


Advances in Aptamer-Based Biosensors and Cell-Internalizing SELEX Technology for Diagnostic and Therapeutic Application.

Gan Z, Roslan M, Shukor M, Halim M, Yasid N, Abdullah J Biosensors (Basel). 2022; 12(11).

PMID: 36354431 PMC: 9687594. DOI: 10.3390/bios12110922.


The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.

Aupy P, Echevarria L, Relizani K, Goyenvalle A Biomedicines. 2017; 6(1).

PMID: 29271929 PMC: 5874659. DOI: 10.3390/biomedicines6010002.


Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.

Hays E, Duan W, Shigdar S Int J Mol Sci. 2017; 18(12).

PMID: 29189740 PMC: 5751179. DOI: 10.3390/ijms18122576.


Rapid Complexation of Aptamers by Their Specific Antidotes.

Stoll H, Steinle H, Wilhelm N, Hann L, Kunnakattu S, Narita M Molecules. 2017; 22(6).

PMID: 28594360 PMC: 6152687. DOI: 10.3390/molecules22060954.